Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The role of chemoprevention by selective cyclooxygenase-2 inhibitors in colorectal cancer patients - a population-based study.

Yang YH, Yang YH, Cheng CL, Ho PS, Ko YC.

BMC Cancer. 2012 Dec 6;12:582. doi: 10.1186/1471-2407-12-582.

2.
3.

Cyclooxygenase as a target for colorectal cancer chemoprevention.

Moreira L, Castells A.

Curr Drug Targets. 2011 Dec;12(13):1888-94. Review.

PMID:
21158711
4.

Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors.

Harris RE, Beebe-Donk J, Alshafie GA.

BMC Cancer. 2008 Aug 14;8:237. doi: 10.1186/1471-2407-8-237.

5.

Use of NSAIDs for the chemoprevention of colorectal cancer.

Herendeen JM, Lindley C.

Ann Pharmacother. 2003 Nov;37(11):1664-74. Review.

PMID:
14565811
6.

A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas.

Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A, Bolognese JA, Oxenius B, Horgan K, Loftus S, Morton DG; APPROVe Trial Investigators.

Gastroenterology. 2006 Dec;131(6):1674-82. Epub 2006 Sep 1.

PMID:
17087947
7.

Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force.

Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D; U.S. Preventive Services Task Force.

Ann Intern Med. 2007 Mar 6;146(5):376-89. Review.

PMID:
17339623
8.

Statin use and risk of colorectal cancer.

Coogan PF, Smith J, Rosenberg L.

J Natl Cancer Inst. 2007 Jan 3;99(1):32-40.

PMID:
17202111
9.

COX-2 polymorphisms and colorectal cancer risk: a strategy for chemoprevention.

Pereira C, Pimentel-Nunes P, Brandão C, Moreira-Dias L, Medeiros R, Dinis-Ribeiro M.

Eur J Gastroenterol Hepatol. 2010 May;22(5):607-13. doi: 10.1097/MEG.0b013e3283352cbb.

PMID:
20075740
10.

Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study.

Vinogradova Y, Hippisley-Cox J, Coupland C, Logan RF.

Gastroenterology. 2007 Aug;133(2):393-402. Epub 2007 May 21.

PMID:
17681160
11.

Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.

Arber N.

Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1852-7. doi: 10.1158/1055-9965.EPI-08-0167. Review.

12.

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.

Veitonmäki T, Tammela TL, Auvinen A, Murtola TJ.

Eur J Cancer. 2013 Mar;49(4):938-45. doi: 10.1016/j.ejca.2012.09.030. Epub 2012 Oct 15.

PMID:
23079475
13.

Exposure to cyclooxygenase-2 inhibitors and risk of cancer: nested case-control studies.

Vinogradova Y, Coupland C, Hippisley-Cox J.

Br J Cancer. 2011 Jul 26;105(3):452-9. doi: 10.1038/bjc.2011.252. Epub 2011 Jul 12.

14.

Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.

Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397.

PMID:
19947799
15.

Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies.

Harris RE, Beebe-Donk J, Alshafie GA.

Subcell Biochem. 2007;42:193-212. Review.

PMID:
17612052
16.

Cyclooxygenase-2 inhibitors in colorectal cancer.

Stoehlmacher J, Lenz HJ.

Semin Oncol. 2003 Jun;30(3 Suppl 6):10-6. Review.

PMID:
12802790
17.

Chemoprevention of colorectal cancer.

Das D, Arber N, Jankowski JA.

Digestion. 2007;76(1):51-67. Epub 2007 Oct 19. Review.

PMID:
17947819
18.

Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population.

Shaya FT, Blume SW, Blanchette CM, Weir MR, Mullins CD.

Arch Intern Med. 2005 Jan 24;165(2):181-6.

PMID:
15668364
19.

Risk of colorectal cancer in type 2 diabetic patients: a population-based cohort study.

Wang JY, Chao TT, Lai CC, Wang CY, Wu VC, Wang SM, Lin HI, Tang SH, Lin HW.

Jpn J Clin Oncol. 2013 Mar;43(3):258-63. doi: 10.1093/jjco/hys228. Epub 2013 Jan 3.

PMID:
23288931
20.

The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.

Rahme E, Barkun AN, Toubouti Y, Bardou M.

Gastroenterology. 2003 Aug;125(2):404-12.

PMID:
12891542

Supplemental Content

Support Center